Bao Pharma announced that it has received $100 million in funding from Shenzhen Oriental Fortune Capital Co., Ltd., Finnova Capital, Haitong Innovation Private Fund Management Co., Ltd., Shanghai Sun Rock Capital Management Co., Ltd., Center Laboratories, Inc.
August 24, 2022
Share
Bao Pharma announced that it has received $100,000,000 in a round of funding led by Shenzhen Oriental Fortune Capital Co., Ltd. on August 25, 2022. The transaction included participation from Finnova Capital, Haitong Innovation Private Fund Management Co., Ltd., Shanghai Sun Rock Capital Management Co., Ltd., Center Laboratories, Inc.
Center Laboratories, Inc. is a Taiwan-based company principally engaged in the production, marketing and distribution of infant nutrition products, as well as the research and development, processing, production, packaging, marketing and sales of dairy products. The Company's main products include dairy products and probiotic products. The Company is also involved in the manufacture, wholesale and retail of western medicines. The Company distributes its products in the domestic market and to overseas markets.
Bao Pharma announced that it has received $100 million in funding from Shenzhen Oriental Fortune Capital Co., Ltd., Finnova Capital, Haitong Innovation Private Fund Management Co., Ltd., Shanghai Sun Rock Capital Management Co., Ltd., Center Laboratories, Inc.
CENTER LABORATORIES, INC. 
